KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2016 - 2025)

Ionis Pharmaceuticals has reported Current Deferred Revenue over the past 17 years, most recently at $73.8 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $73.8 million for Q4 2025, down 6.62% from a year ago — trailing twelve months through Dec 2025 was $73.8 million (down 6.62% YoY), and the annual figure for FY2025 was $73.8 million, down 6.62%.
  • Current Deferred Revenue for Q4 2025 was $73.8 million at Ionis Pharmaceuticals, down from $77.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for IONS hit a ceiling of $204.8 million in Q3 2023 and a floor of $73.8 million in Q4 2025.
  • Median Current Deferred Revenue over the past 5 years was $93.7 million (2022), compared with a mean of $100.6 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 105.83% in 2023 and later plummeted 62.89% in 2024.
  • Ionis Pharmaceuticals' Current Deferred Revenue stood at $97.7 million in 2021, then fell by 7.3% to $90.6 million in 2022, then skyrocketed by 66.85% to $151.1 million in 2023, then plummeted by 47.73% to $79.0 million in 2024, then decreased by 6.62% to $73.8 million in 2025.
  • The last three reported values for Current Deferred Revenue were $73.8 million (Q4 2025), $77.0 million (Q3 2025), and $75.9 million (Q2 2025) per Business Quant data.